These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32017902)

  • 1. Evaluation of Particle Techniques for the Characterization of Subvisible Particles From Elastomeric Closure Components.
    Rech J; Fradkin A; Krueger A; Kraft C; Paskiet D
    J Pharm Sci; 2020 May; 109(5):1725-1735. PubMed ID: 32017902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals.
    Felsovalyi F; Janvier S; Jouffray S; Soukiassian H; Mangiagalli P
    J Pharm Sci; 2012 Dec; 101(12):4569-83. PubMed ID: 23023774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product.
    Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P
    J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
    Zhang L; Shi S; Antochshuk V
    J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues and challenges of subvisible and submicron particulate analysis in protein solutions.
    Scherer TM; Leung S; Owyang L; Shire SJ
    AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product.
    Bai S; Landsman P; Spencer A; DeCollibus D; Vega F; Temel DB; Houde D; Henderson O; Brader ML
    J Pharm Sci; 2016 Jan; 105(1):50-63. PubMed ID: 26852839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying the Vial Capping Process: Residual Seal Force and Container Closure Integrity.
    Ovadia R; Streubel A; Webb-Vargas Y; Ulland L; Luemkemann J; Rauch K; Eder J; Lam P; Tegoulia V; Maa YF
    PDA J Pharm Sci Technol; 2019; 73(1):2-15. PubMed ID: 29954924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subvisible Particulate Contamination in Cell Therapy Products-Can We Distinguish?
    Vollrath I; Mathaes R; Sediq AS; Jere D; Jörg S; Huwyler J; Mahler HC
    J Pharm Sci; 2020 Jan; 109(1):216-219. PubMed ID: 31521641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended Characterization and Impact of Visible Fatty Acid Particles - A Case Study With a mAb Product.
    Saggu M; Demeule B; Jiang L; Kammerer D; Nayak PK; Tai M; Xiao N; Tomlinson A
    J Pharm Sci; 2021 Mar; 110(3):1093-1102. PubMed ID: 33271136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shape Characterization of Subvisible Particles Using Dynamic Imaging Analysis.
    Mathaes R; Manning MC; Winter G; Engert J; Wilson GA
    J Pharm Sci; 2020 Jan; 109(1):375-379. PubMed ID: 31476311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Governing the Accuracy of Subvisible Particle Counting Methods.
    Ríos Quiroz A; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    J Pharm Sci; 2016 Jul; 105(7):2042-52. PubMed ID: 27287519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for design and use of container challenge sets for qualification and validation of visible particulate inspection.
    Melchore JA; Berdovich D
    PDA J Pharm Sci Technol; 2012; 66(3):273-84. PubMed ID: 22634593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
    Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
    J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.